<DOC>
	<DOC>NCT00541489</DOC>
	<brief_summary>To study the efficacy and safety of Naproxcinod vs. Placebo and Naproxen in the treatment of signs and symptoms of Osteoarthritis.</brief_summary>
	<brief_title>Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip</brief_title>
	<detailed_description>This is a 13 week randomized, double-blind, parallel group, multicenter study comparing efficacy and safety of Naproxcinod, Placebo and Naproxen.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Hip</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>Men and women (40 or older) with a diagnosis of primary OA of the hip Must be a current chronic user of NSAIDS or acetaminophen Must discontinue all analgesic therapy at Screening Uncontrolled Hypertension or Diabetes Hepatic or renal impairment Current or expected use of anticoagulant Clinically relevant abnormal ECG A history of alcohol or drug abuse Diagnosis of gastric or duodenal ulceration and/or history of significant gastroâ€‘duodenal bleeding, within the last 6 months Current medical disease, including arthritic, that could confound or interfere with the evaluation of efficacy Candidates for imminent joint replacement Participation within 30 days prior to screening in another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Osteoarthritis, Hip</keyword>
</DOC>